1160 patients across Europe were a part of a recent study to see just how effective onabotulinumtoxinA (sometimes sold under the brand name Botox) was in treating patients with chronic migraine. We all hear stories, but if you take a large sample, what are the results?
First, a little background. This group was 15.8% male and 84.2% female. The mean age was 46.6 years old. About half of them had used Botox before. The study had data from over 4000 treatments.
The basic good news was that most patients – 74.4% – were satisfied or even extremely satisfied with their treatment.
This tells us that the treatment is helping, but not how much it’s helping. But for those who are curious, the treatment usually involved about 31 injection sites and a dose of 155 U. Treatments tended to be about 13-14 weeks apart, or just over 3 months.
The most commonly reported side effect was neck pain.
As we have talked about before, onabotulinumtoxinA treatment is helping migraine patients, but there is reason to believe it could be helping a lot more. There are a lot of variables that we would like to know more about. Which type of migraine is most responsive to this treatment? Which injection sites are the best? Could we get the same results with a lower dosage?
Now that we’ve seen the data, what’s your experience? Leave a comment!